Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > GCGR

GCGR

Brief Information

Name:Glucagon receptor
Target Synonym:GL-R,GCGR,Glucagon Receptor,GGR,Receptors, Glucagon
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:24
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
GCR-M5254 Mouse Mouse GCGR / Glucagon receptor Protein, Fc Tag
GCR-M5254-structure
GCR-M5254-sds
GCR-H52H3 Human Human GCGR / Glucagon receptor Protein, His Tag (MALS verified)
GCR-H52H3-structure
GCR-H52H3-sds

Part of Bioactivity data

GCR-H52H3-ELISA
Human GCGR, His Tag (Cat. No. ) MALS images

The purity of Human GCGR, His Tag (Cat. No. GCR-H52H3) is more than 85% and the molecular weight of this protein is around 23-33 kDa verified by SEC-MALS.

Report
  • Background
    G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.
  • Clinical and Translational Updates
      

  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

Glucagon R, GCGR,Glucagon receptor

Background

G-protein coupled receptor for glucagon that plays a central role in the regulation of blood glucose levels and glucose homeostasis. Regulates the rate of hepatic glucose production by promoting glycogen hydrolysis and gluconeogenesis. Plays an important role in mediating the responses to fasting. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Promotes activation of adenylate cyclase. Besides, plays a role in signaling via a phosphatidylinositol-calcium second messenger system.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Glucagon intranasal (Eli Lilly/Locemia Solutions) AMG504-1; LY-900018 Approved Amg Medical, Locemia Solutions Hypoglycemia Details
Glucagon (rDNA origin, Novo Nordisk) GL-G Approved Novo Nordisk A/S GlucaGen, Glucagon G Japan Hypoglycemia Novo Nordisk A/S 1998-06-22 Hypoglycemia Details
Glucagon (Xeris Pharmaceuticals) Approved Xeris Pharmaceuticals Inc Gvoke United States Hypoglycemia Xeris Pharmaceuticals Inc 1960-01-01 Hypoglycemia Details
Glucagon (rDNA origin, Lilly) Approved Eli Lilly And Company Glucagon United States Hypoglycemia Eli Lilly And Company 1998-09-11 Diabetes Mellitus, Type 1; Hypoglycemia; Insulin Resistance; Obesity Details
Dasiglucagon ZP-GA-1; ZP-4207 Approved Zealand Pharma A/S Zegalogue United States Hypoglycemia Zealand Pharma Us Inc 2021-03-22 Congenital Hyperinsulinism; Diabetes Mellitus, Type 1; Hypoglycemia; Hyperinsulinism; Glucose Metabolism Disorders Details
Glucagon MP-123456B Approved Eli Lilly And Company Baqsimi, Ogluo EU Hypoglycemia Eli Lilly Nederland Bv 1960-11-14 Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PRT-001 PRT-001 Phase 3 Clinical Particle Therapeutics Hypoglycemia Details
PRT-003 PRT-003 Phase 1 Clinical Particle Therapeutics Details
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida) Phase 1 Clinical Translational Research Institute For Metabolism And Diabetes Obesity Details
Isosteviol ISV; STX-03 Phase 2 Clinical Stevia Pharma Diabetes Mellitus, Type 2 Details
Human glucagon(Shanghai Duomirui) Phase 1 Clinical Shanghai Duomirui Biotechnology Co Ltd Hypoglycemia Details
PB-718 PB-718 Phase 1 Clinical Peg Bio Co Ltd Non-alcoholic Fatty Liver Disease; Obesity Details
Oxyntomodulin long-acting (Pharmsynthez/Xenetic Biosciences) Phase 2 Clinical Pharmsynthez, Xenetic Biosciences Diabetes Mellitus, Type 2; Obesity Details
Glucagon analogue G-530-L; NN-9030; NNC9204-0530 Novo Nordisk A/S Details
Stable glucagon (Albireo Pharma) BIOD-961; BIOD-962 Albireo Details
Cotadutide MEDI-0382 Phase 1 Clinical Medimmune Llc Non-alcoholic Fatty Liver Disease Details
DD-01 DD-01 Neuraly Inc, D&D Pharmatech Details
Oxyntomodulin (Merck & Co) Merck Sharp & Dohme Corp, Xenetic Biosciences Details
DR-10624 DR-10624 Phase 1 Clinical Zhejiang Doer Biologics Corp Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome; Obesity; Diabetes Mellitus Details
ISIS-325568 ISIS-325568 Ionis Pharmaceuticals Inc Details
MK-3577 MK-3577 Merck Sharp & Dohme Corp Details
Adomeglivant 74Z5ZL2KVG; LY-2409021 Eli Lilly And Company Details
NNC-92041706 NNC9204-1706; NNC-92041706; NN-9423; NNC-92041706-A Novo Nordisk A/S Details
IONIS-GCGRRx IONIS-GCGRRx; ISIS-449884; ISISGCGRRx Phase 2 Clinical Ionis Pharmaceuticals Inc Diabetes Mellitus, Type 2 Details
Bamadutide SAR-425899 Sanofi Details
MK-0893 MK-0893; L-001241689 Merck & Co Inc Details
Pegapamodutide WG4ID2U7FT; TT-401; LY-2944876; OPK-88003 Eli Lilly And Company Details
PF-06291874 PF-6291874; PF-06291874 Pfizer Inc Details
Mazdutide OXM-3; IBI-362; LY-3305677 Phase 2 Clinical Eli Lilly And Company Diabetes Mellitus, Type 2; Obesity; Overweight Details
MK-5823 MK-5823 Merck Sharp & Dohme Corp Details
MK-8521 MK-8521 Merck Sharp & Dohme Corp Details
LGD-6972 LGD-6972; MB-11262; RVT-1502 Ligand Pharmaceuticals Inc Details
Glucagon biosimilar (Hospira) Hospira Details
Crotedumab REGN-1193 Sanofi, Regeneron Pharmaceuticals Inc Details
Pemvidutide ALT-801(Altimmune); SP-1373; VPD-107 Velocity Pharmaceutical Development Details
BioChaperone Glucagon BC Glucagon Adocia Details
Efocipegtrutide HM-15211 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Non-alcoholic Fatty Liver Disease; Obesity Details
HM-15136 HM-15136 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Congenital Hyperinsulinism; Diabetes Mellitus, Type 2 Details
Efinopegdutide JNJ-64565111; HM-12525A; JNJ-5111; MK-6024 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Diabetes Mellitus, Type 2; Non-alcoholic Fatty Liver Disease; Obesity; Kidney Failure, Chronic Details
LY-3437943 LY-3437943 Phase 2 Clinical Eli Lilly And Company Diabetes Mellitus, Type 2; Obesity; Overweight Details
BI-456906 BI-456906 Phase 2 Clinical Zealand Pharma A/S Non-alcoholic Fatty Liver Disease; Diabetes Mellitus, Type 2; Liver Cirrhosis; Liver Diseases; Obesity; Overweight Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap